Professor Sir Mark Pepys and Professor Philip Hawkins established the National Amyloidosis Centre in 1999 with direct funding from the Department of Health. The Centre has grown steadily and now sees more than 4,000 patients each year.
Research and development of new treatments for amyloidosis in the Centre have made enormous contributions to understanding of the disease and to improved outcomes for patients.
These achievements have been recognised by the award of large research grants and by the generous funding of patient care by the NHS. However, award of formal research grants takes many months and is tied to particular uses.
There is always a need for flexible research funds which can be used whenever required for developments and to support new ideas.
The UCL Amyloidosis Research Fund, a charitable fund within University College London (UCL), was created to serve this function and receives donations from patients, relatives and other supporters.
It is an invaluable resource for the Centre, enabling crucial developments for the benefit of patients which would otherwise not have been possible. Cutting edge state-of-the-art research demands flexibility and immediate access to funding to enable exciting and promising new avenues to be explored in a timely fashion, through purchase of sophisticated new equipment and employment or redeployment of highly qualified scientific and medical staff.
The resources provided by the UCL Amyloidosis Research Fund, through the generosity of donors, will undoubtedly make major contributions to alleviating the suffering and saving the lives of many thousands of individuals afflicted by a terrible and hitherto incurable disease. Every penny is received with sincere gratitude and is used specifically and in its entirety for amyloidosis research.